SLOTS-CAPITAL
11.6.2021 11:24:04 CEST | Business Wire | Pressemeddelelse
Slots Capital, et af de mest populære online casinoer i verden, er nu tilgængelig for flere spillere end nogensinde før, når de for første gang lander i flere nye lande.
Det betyder, at spillere i Belgien, Rumænien, Grækenland, Danmark, Finland, Irland, Letland og Luxembourg nu kan nyde godt af den førsteklasses online casinooplevelse, som Slots Capital tilbyder.
Hvis du elsker spillemaskiner, så er Slots Capital stedet, hvor du kan vælge mellem mere end 300 spil fra kendte udviklere såsom Rival, Saucify, Dragon og Qora.
Faktisk har vi for nylig styrket vores spillemaskiner og bordspil-lobby med titler fra eftertragtede spilstudier, herunder Rival Gaming, Dragon Gaming, Saucify Gaming og Qora Gaming.
Vi vil også tilføje spillemaskiner fra Arrow's Edge i de kommende uger, men i mellemtiden kan spillere prøve de nyeste titler ved at udforske vores lobby, som inkluderer:
- Dead Beats
- Irish Wishes
- Lucky Macau
- Panda Playtime
- Sands of Space
- Twin Dragons
- Viking Victory
- Win Another Day
- Wrath of Medusa
- Yeti Hunt i3D
Slots Capital er ikke kun kendt for at være den bedste destination for spillemaskiner, vores spillere elsker også de daglige bonusser, bonusser uden indbetaling, superhurtige udbetalinger og 24/7 kundesupport.
Vi er mobilvenlige, hvilket betyder, at du kan tilgå alle vores spillemaskiner samt vores generøse bonusser, betalingsmuligheder og kundesupport fra din smartphone eller tablet.
Hos Slots Capital vil vi gerne byde nye spillere velkommen med en enorm generøs indbetalingsmatchbonus; når du indbetaler 150 kr., tilføjer vi 450 kr. til din saldo, hvilket giver dig 600 kr. at spille med totalt.
Hvis ikke det var nok, tilbyder vi også match-bonusser på dine næste tre indbetalinger, hvor du kan modtage 250 %, 300 % og 400 %!
Sharon Kane, Slots Capital , udtalte: "Vi er så begejstrede over at have lanceret Slots Capital på otte nye markeder, og for at spillere kan nyde en af de bedste online casinooplevelser på markedet.
Vi har for nylig føjet en række efterspurgte udbydere til vores allerede imponerende lobby, hvilket viser vores engagement til at tilbyde spillere det bredest-mulige udvalg af spillemaskiner at vælge imellem.
Hvis du ikke allerede har spillet hos Slots Capital, hvad venter du så på - udnyt vores gavmilde velkomsttilbud og kom og se, hvad alle taler om."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210611005178/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum